Skip to content

Author

Michela Cadarso

We have 3 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations
#protein folding Sep 2026

Abstract B052: Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition

The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.

Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.